What is Nls Pharmaceutics Ltd's earnings per share (EPS)?

Nls Pharmaceutics Ltd (NLSP) reported diluted earnings per share of $2.16 for fiscal year 2025. This represents a -11.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nls Pharmaceutics Ltd Financials

NLSP

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Nls Pharmaceutics Ltd (NLSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nls Pharmaceutics Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Nls Pharmaceutics Ltd carries a low D/E ratio of 0.58, meaning only $0.58 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 90/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nls Pharmaceutics Ltd's current ratio of 0.76 is below the typical benchmark, resulting in a score of 10/100. However, the company holds substantial cash reserves (52% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Returns

Nls Pharmaceutics Ltd generates a -114.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -140.9% the prior year.

Piotroski F-Score Weak

3/9

Nls Pharmaceutics Ltd passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.33x

For every $1 of reported earnings, Nls Pharmaceutics Ltd generates $0.33 in operating cash flow (-$2.8M OCF vs -$8.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$2.5M

YoY-51.7%

Nls Pharmaceutics Ltd's EBITDA was -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 51.7% from the prior year.

Net Income

-$8.3M

YoY-319.0%

Nls Pharmaceutics Ltd reported -$8.3M in net income in fiscal year 2025. This represents a decrease of 319.0% from the prior year.

EPS (Diluted)

$2.16

YoY-11.1%

Nls Pharmaceutics Ltd earned $2.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 11.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$2.8M

YoY-158.8%

Nls Pharmaceutics Ltd generated -$2.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 158.8% from the prior year.

Cash & Debt

$2.2M

YoY+238.6%

5Y CAGR+88.0%

Nls Pharmaceutics Ltd held $2.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+51.8%

Nls Pharmaceutics Ltd had 5M shares outstanding in fiscal year 2025. This represents an increase of 51.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-114.5%

YoY+26.4pp

Nls Pharmaceutics Ltd's ROE was -114.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 26.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.1M

YoY+13.5%

5Y CAGR+62.4%

Nls Pharmaceutics Ltd invested $1.1M in research and development in fiscal year 2025. This represents an increase of 13.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$8K

YoY+33.3%

Nls Pharmaceutics Ltd invested $8K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 33.3% from the prior year.

NLSP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.1M+13.5%	$992K-38.3%	$1.6M-82.1%	$9.0M+51.6%	$5.9M+5844.4%	$100K
SG&A Expenses	$1.3M+67.5%	$805K-39.3%	$1.3M-79.6%	$6.5M+9.5%	$5.9M+170.1%	$2.2M
Operating Income	-$2.6M-24.0%	-$2.1M+31.5%	-$3.0M+80.5%	-$15.5M-30.5%	-$11.9M-415.8%	-$2.3M
Interest Expense	N/A	$45K-62.4%	$120K+26.0%	$95K+97.9%	$48K-44.6%	$87K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$8.3M-319.0%	-$2.0M+40.6%	-$3.3M+79.8%	-$16.5M-38.1%	-$11.9M-317.5%	-$2.9M
EPS (Diluted)	$2.16-11.1%	$2.43	$1.13+103.4%	$-33.52-3252.0%	$-1.00-143.9%	$-0.41

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NLSP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.4M+1167.4%	$903K-51.1%	$1.8M-80.1%	$9.3M+60.9%	$5.8M+375.8%	$1.2M
Current Assets	$3.2M+307.9%	$780K-57.2%	$1.8M-80.3%	$9.2M+61.6%	$5.7M+2809.4%	$197K
Cash & Equivalents	$2.2M+238.6%	$650K-43.3%	$1.1M-87.2%	$8.9M+64.8%	$5.4M+5695.7%	$94K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.7M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.2M-52.9%	$8.9M+192.4%	$3.0M-66.8%	$9.2M+75.5%	$5.2M-48.8%	$10.2M
Current Liabilities	$4.2M-52.9%	$8.9M	N/A	$3.4M+39.8%	$2.4M-66.6%	$7.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$113K
Total Equity	$7.3M+190.7%	-$8.0M-568.0%	-$1.2M-1178.4%	$111K-79.5%	$542K+106.0%	-$9.0M
Retained Earnings	-$84.9M-10.8%	-$76.6M-8.8%	-$70.4M-20.9%	-$58.2M-39.6%	-$41.7M-40.1%	-$29.8M

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Total Assets	$11.4M+163.9%	$4.3M+380.4%	$903K-24.3%	$1.2M-35.4%	$1.8M-18.7%	$2.3M-75.5%	$9.3M+350.7%	$2.1M
Current Assets	$3.2M-21.2%	$4.0M+417.4%	$780K-34.6%	$1.2M-34.6%	$1.8M-18.8%	$2.2M-75.7%	$9.2M+357.2%	$2.0M
Cash & Equivalents	$2.2M-28.4%	$3.1M+372.7%	$650K+17.6%	$553K-51.8%	$1.1M-30.6%	$1.7M-81.5%	$8.9M+560.8%	$1.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.2M+188.3%	$1.5M-83.6%	$8.9M-14.9%	$10.5M+243.7%	$3.0M-53.6%	$6.6M-28.5%	$9.2M+50.3%	$6.1M
Current Liabilities	$4.2M	N/A	$8.9M+15.3%	$7.7M	N/A	$3.9M+15.9%	$3.4M-1.5%	$3.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$7.3M+151.5%	$2.9M+136.0%	-$8.0M+13.7%	-$9.3M-674.3%	-$1.2M+72.1%	-$4.3M-3962.0%	$111K+102.7%	-$4.0M
Retained Earnings	-$84.9M-13.5%	-$74.8M+2.3%	-$76.6M-5.8%	-$72.4M-2.9%	-$70.4M-6.9%	-$65.8M-13.1%	-$58.2M-15.6%	-$50.3M

NLSP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$2.8M-159.5%	-$1.1M+69.0%	-$3.4M+75.2%	-$13.9M+7.1%	-$14.9M-1947.8%	-$729K
Capital Expenditures	$8K+33.3%	$6K0.0%	$6K	N/A	$40K	N/A
Free Cash Flow	-$2.8M-158.8%	-$1.1M+68.9%	-$3.5M	N/A	-$15.0M	N/A
Investing Cash Flow	$1.7M+28433.3%	-$6K-105.8%	$103K	N/A	-$40K	N/A
Financing Cash Flow	$2.6M+484.2%	$450K-84.2%	$2.8M-83.6%	$17.4M-14.5%	$20.3M+3939.1%	$504K
Dividends Paid	N/A	$2.1M	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NLSP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-114.5%+26.4pp	-140.9%	N/A	-14861.0%-12658.5pp	-2202.5%	N/A
Return on Assets	-72.5%+16.2pp	-88.7%+91.7pp	-180.4%-2.6pp	-177.8%+29.4pp	-207.2%+28.9pp	-236.2%
Current Ratio	0.76+0.7	0.09	N/A	2.75+0.4	2.38+2.4	0.03
Debt-to-Equity	0.58+1.7	-1.11	N/A	82.57+72.9	9.63+9.6	-0.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.76	N/A	0.09-0.1	0.15	N/A	0.58-2.2	2.75+2.2	0.59
Debt-to-Equity	0.58+0.1	0.50+1.6	-1.11+0.0	-1.13	N/A	-1.53-84.1	82.57+84.1	-1.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.76), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

In8Bio, Inc. INAB

$15.5M

Aeon Biopharma AEON

$22.7M

Creative Med Technology Hldgs CELZ

$8.4M

Cyclacel Phar Pr CYCCP

$9.6M

Dogwood Therapeutics DWTX

$61.5M

Frequently Asked Questions

Is Nls Pharmaceutics Ltd profitable?

No, Nls Pharmaceutics Ltd (NLSP) reported a net income of -$8.3M in fiscal year 2025.

What is Nls Pharmaceutics Ltd's EBITDA?

Nls Pharmaceutics Ltd (NLSP) had EBITDA of -$2.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Nls Pharmaceutics Ltd's return on equity (ROE)?

Nls Pharmaceutics Ltd (NLSP) has a return on equity of -114.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Nls Pharmaceutics Ltd's free cash flow?

Nls Pharmaceutics Ltd (NLSP) generated -$2.8M in free cash flow during fiscal year 2025. This represents a -158.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nls Pharmaceutics Ltd's operating cash flow?

Nls Pharmaceutics Ltd (NLSP) generated -$2.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Nls Pharmaceutics Ltd's total assets?

Nls Pharmaceutics Ltd (NLSP) had $11.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nls Pharmaceutics Ltd's capital expenditures?

Nls Pharmaceutics Ltd (NLSP) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Nls Pharmaceutics Ltd spend on research and development?

Nls Pharmaceutics Ltd (NLSP) invested $1.1M in research and development during fiscal year 2025.

How many shares does Nls Pharmaceutics Ltd have outstanding?

Nls Pharmaceutics Ltd (NLSP) had 5M shares outstanding as of fiscal year 2025.

What is Nls Pharmaceutics Ltd's current ratio?

Nls Pharmaceutics Ltd (NLSP) had a current ratio of 0.76 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Nls Pharmaceutics Ltd's debt-to-equity ratio?

Nls Pharmaceutics Ltd (NLSP) had a debt-to-equity ratio of 0.58 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nls Pharmaceutics Ltd's return on assets (ROA)?

Nls Pharmaceutics Ltd (NLSP) had a return on assets of -72.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Nls Pharmaceutics Ltd's cash runway?

Based on fiscal year 2025 data, Nls Pharmaceutics Ltd (NLSP) had $2.2M in cash against an annual operating cash burn of $2.8M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Nls Pharmaceutics Ltd's Piotroski F-Score?

Nls Pharmaceutics Ltd (NLSP) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nls Pharmaceutics Ltd's earnings high quality?

Nls Pharmaceutics Ltd (NLSP) has an earnings quality ratio of 0.33x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Nls Pharmaceutics Ltd?

Nls Pharmaceutics Ltd (NLSP) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.